[ 11 C]befloxatone is a high-affinity, reversible, and selective radioligand for the in vivo visualization of the monoamine oxidase A (MAO-A) binding sites using positron emission tomography (PET). The multi-injection approach was used to study in baboons the interactions between the MAO-A binding sites and [
Introduction
Monoamine oxidases (MAO; EC 1.4.3.4) are flavinecontaining enzymes located in the outer membrane of mitochondria. Monoamine oxidases are present in the brain (both neurons and glial cells) and in peripheral tissues. In the brain, MAOs are responsible for the metabolic inactivation of monoamine neurotransmitters and thus have a key role in the regulation of the concentration of these amines. In mammals, two isoforms of the enzyme have been identified on the basis of their biochemical properties, substrate selectivity, and gene products (Shih et al, 1999) . These two isoforms are expressed in distinct cellular compartments within the central nervous system. Monoamine oxidase A is found primarily in catecholaminergic neurons whereas MAO-B is primary localized in serotoninergic neuron and in glial cells (Yu et al, 1992) . According to the available literature, MAO-A could be more important than MAO-B, because it seems to be the main catabolizing enzyme of norepinephrine, serotonine, and dopamine. Dysfunction of MAO is associated with a number of neurologic disorders, including Parkinson's, Alzheimer's and Huntington's diseases, major depression, and schizophrenia (for review see Lewis et al, 2007) . Monoamine oxidases have also been shown to be inhibited by unknown compounds contained in tobacco smoke (Van Amsterdam et al, 2006) . Several lines of evidence indicate that the MAO-A inhibition has a key role in the nicotine addiction (Guillem et al, 2006; Lewis et al, 2007; van Amsterdam et al, 2006; Villegier et al, 2006) .
Until now, the suicide substrate [
11 C]clorgyline has been used in human positron emission tomography (PET) studies for the investigation of drugs, tobacco smoke effects, and aging (for review see Fowler et al, 2005) . The quantification of cerebral binding of deprenyl (MAO-B) and of clorgyline (MAO-A) has been difficult because the irreversible binding of these substrates. This limitation has been partially overcome by the use of deuterium substitution at the a-carbon, which reduces the reaction rate so that the net blood-brain clearance can be calculated for deprenyl. But, in the case of deuterium-clorgyline, there was a decrease in the contrast of parametric images because of some nonspecific binding (Logan et al, 2002) .
During the past decade, attention has focused on the development of reversible MAO inhibitors that are advantageous in therapeutic uses with possibly less side effects than with irreversible inhibitors (Livingston and Livingston, 1996; Wouters, 1998) . Reversible and selective MAO-A inhibitors have been used as antidepressant and antianxiety drugs. Some of them have been radiolabeled and in vivo characterized (Ametamey et al, 1996; Bergströ m et al, 1997a; Bottlaender et al, 2003) . In vivo PET studies in animals and humans have already shown the potential of [
11 C]-harmine for imaging MAO-A (Bergströ m et al, 1997a, b; Jensen et al, 2006; Ginovart et al, 2006) . [ 11 C]-harmine showed favorable kinetics and showed sensitivity to pretreatment with selective MAO-A inhibitors. (R-(À) and (S)-( + )-1-1[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone were also synthetized and characterized in vivo (Jensen et al, 2008) . They presented two obvious advantages over harmine: a simple radiosynthesis with high yield and a slower plasma metabolism. Until now, only [
11 C]-harmine has been used in patients .
Befloxatone, a reversible MAO-A inhibitor, has a high affinity (2 nmol/L) and a high specificity for MAO-A sites (Curet et al, 1996) . The ligand has been labeled with carbon-11 and its pharmacologic characterization was performed in vivo using PET in nonhuman primates . [ 11 C]befloxatone attains rapidly high specific binding in brain after i.v. administration, its selective and reversible binding to MAO-A sites was also confirmed in vivo. Befloxatone appeared safe for its therapeutic use in humans (Rosenzweig et al, 1998) and therefore suitable for clinical PET (Leroy et al, 2009) .
Quantification of brain MAO-A using PET radiotracers is based on a two-compartment model kinetic analysis. When using [
11 C]clorgyline, the parameter l Â k 3 (where l = k 1 /k 2 , and k 3 is the catalytic activity) appears to be a more sensitive index of the inhibition of the enzyme activity than influx constant (K i ) determined with the Patlak graphical method (Lammertsma et al, 1991) . With [
11 C]-harmine, the kinetic modeling analysis (two-compartment model) allowed stable and reliable determination of distribution volumes (V T ) . However, all these methods estimate only indexes of the density of binding sites, which are only proportional to the actual binding site density or to the catalytic activity. The relation of these indexes to the density of binding sites is based on several assumptions such as equilibrium state or the K d stability (Lammertsma et al, 1991; Ginovart et al, 2006) .
The purpose of this study was to quantify the MAO-A site density in the living brain. We used the multi-injection approach that has proved to be a suitable method to estimate the binding site concentrations in vivo using PET: dopamine D2/D3 with fallypride and with FLB-457, benzodiazepine with flumazenil, DAT with CFT, 5-HT1A with MPPF (for review see Morris et al, 2009) , neuronal nicotinic acetylcholine receptors with fluoro-A-85380 (Gallezot et al, 2008) , myocardial muscarinic receptors with MQNB (Delforge et al, 1993 Leriche et al, 2009) , which are more appropriate for clinical research in humans. For the above-mentioned radioligands, it was possible to estimate B max and K d separately using a multipleinjection strategy. There are some instances where this is highly advisable: medical treatments with agonist drugs or smoking that cause receptors to change from high-to low-affinity state. In the case of MAO-A study in smokers, the estimation of B max and K d separately will allow to determine the proportion of reversible and irreversible binding of unknown compounds contained in tobacco smoke.
Simulations led to a precise knowledge of the befloxatone kinetics in all compartments. Furthermore, the these estimations has high clinical relevance as there is a close relationship between density of binding sites and activity of the MAO-A (V max )-the latter directly reflecting the catabolizing activity of the enzyme-as shown in human cerebral cortex and caudate nucleus (O'Carroll et al, 1983 (O'Carroll et al, , 1989 ). . Typically, 5.55 to 9.25 GBq of [
Materials and methods

Radiopharmaceutical Preparation
11 C]befloxatone with a radiochemical-and chemical purity of more than 99% were routinely obtained within 25 mins of radiosynthesis (including high-pressure liquid chromatography purification) with a specific radioactivity (SA) of 11.6 to 22.7 GBq/mmol.
The Ligand-Receptor Model
The part of this model corresponding to befloxatone kinetics is derived from the usual nonequilibrium nonlinear model (Mintun et al, 1984; Huang et al, 1986) . It includes four compartments (unmetabolized ligand in plasma, free ligand in the tissue, ligand specifically bound to receptor sites, and nonspecific binding; Figure 1 ) and seven parameters (the MAO binding site concentration (B 0 max ) and six kinetic parameters describing the kinetics between the compartments (K 1 , k 2 , k 5 , k 6 and the apparent association and dissociation rate constants k on /V R , and k off )). The reaction volume V R allows taking into account the possibility that the mean free ligand concentration in the vicinity of the receptor sites may be different from that in the entire tissue (Delforge et al, 1996) . In the multiinjection approach, unlabeled doses of ligand are injected, and thus, the kinetics of this unlabeled ligand has to be simulated. Detailed descriptions and discussions of this procedure have been published previously (Morris et al, 2004; Gallezot et al, 2008) .
Experimental Protocol
All animal use procedures were in strict accordance with the recommendations of the European Economic Community (86/609/CEE) and the French National Committee (décret 87/848) for the care and use of laboratory animals.
Five PET experiments were performed on five male Papio anubis (weight 13 ± 1 kg). Anesthesia was maintained with 1% isoflurane and a mixture of 66:33 nitrous oxide/oxygen, controlled by a ventilator (Ohmeda OAV 7710; Ohmeda Madison, WI, USA). The baboon's head was fixed in a head holder and positioned in the scanner gantry. A transmission scan ( 68 Ge rods, 15 mins) was recorded to correct for g ray attenuation of subsequent emission scan.
The experimental protocol included three injections:
a tracer dose of [ 11 C]befloxatone: 16.9±5 nmol, specific activity (SA) = 16 ± 4 GBq/mmol, two successive coinjections of labeled and unlabeled befloxatone at 40 and 80 mins (808±94 and 7719 ± 912 nmol), respectively.
Labeled Ligand Unlabeled Ligand Figure 1 The plasma concentration of the unlabeled and unmetabolized ligand (denoted as C a (t)) was estimated using the curve C a * (t) corresponding to the labeled ligand. The flux of [ 11 C]befloxatone from the arterial plasma compartment to the free compartment is given by K 1 C a * (t). The free ligand can bind to an unoccupied specific receptor site, or escape back to the blood circulation with a rate constant k 2 . The quantity of free labeled ligand present in 1 mL of the tissue volume is denoted by M f * (t). However, because of the obvious heterogeneity of the tissue, this concentration can be heterogeneous in the PET volume. To take into account this heterogeneity, the concept of reaction volume, denoted by V R , has been introduced (Delforge et al, 1996) . By definition, the value of V R is such that M f * (t)/V R is equal to the local free ligand concentration in the vicinity of the receptor sites. The specific binding is a saturable reaction that depends on the bimolecular association rate constant k on , the free ligand concentration in the vicinity of the receptors sites M f * (t)/V R , and the quantity of free receptors in 1 mL of tissue. This last quantity is equal to B
is the total receptor site concentration available for binding. M b * (t) and M b (t) are the quantities of receptors sites in 1 mL of tissue already occupied by the labeled and unlabeled ligands, respectively. The rate constant for the dissociation of the specifically bound ligand is denoted by k off . The in vivo equilibrium dissociation rate constant is denoted by K d V R , where K d is the ratio k off /k on . The simulated PET data (denoted as M TEP * (t)) corresponding to the PET scan performed between time t i and t i + 1 are given by the following equation:
where C b * (t) is the whole blood time-concentration curve and where F V represents the fraction of blood present in the tissue volume.
The overall duration of the experiment was 120 mins. In two experiments, the amount of [ 11 C]befloxatone produced by a single radiosynthesis was large enough to perform the three sequential injections despite of the rapid carbon-11 physical decay. However, in the three other experiments, to maintain a high count rate till the end of the scan, a second radiosynthesis was needed for the last coinjection (80 mins).
Input Function and Metabolite Studies
The input function was the arterial plasma unmetabolized [ 11 C]befloxatone. Arterial blood samples were withdrawn from the femoral artery at designated times. Blood and plasma radioactivity was measured in a g-counter and the time-activity curves were corrected for [
11 C] decay from the time of the first injection.
The amount of unchanged radiotracer in plasma was measured (15 samples) with high-pressure liquid chromatography. After deproteinization with acetonitrile, the samples were centrifuged and the supernatant was injected directly into the high-pressure liquid chromatography column. The column (reverse-phase Waters Bondapak C18 column (300 Â 7.8 mm, 10 mm)) was eluted applying a gradient from 20% acetonitrile in 0.01 mol/L phosphoric acid up to 80% in 5.5 mins, up to 90% at 7.5 mins, and returned back to 20% at 7.6 mins with a total run length of 10 mins. The flow rate of the eluent was maintained at 6 mL/min. Befloxatone was eluted with a retention time of 6 mins. The data acquisition and analysis were performed using Winflow software (version 1.21; JMBS Developments, Grenoble, France).
Magnetic Resonance Imaging
An MRI examination was performed for each animal to provide detailed anatomical images. The examinations were performed with a 1.5 T SIGNA system (General Electric, Milwaukee, WI, USA) and a custom-made receive-only coil was used in proximity to the baboon's head to provide higher sensitivity. The animal was anesthetized (ketamine/xylazine, 15:1.5 mg/kg, i.m.) and positioned using a stereotaxic head holder. The imaging protocol used a T 1 -weighted inversion-recovery sequence in three-dimensional mode and a 256 Â 192 matrix over 124 slices of 1.5 mm in thickness.
PET Measurements and Data Analysis
Positron emission tomography studies were performed with a high-resolution tomograph (ECAT 953B/31; Siemens Medical Solutions, Knoxville, TN, USA), which allowed reconstruction of 31 slices every 3.3 mm with spatial and axial resolution of 5.7 and 5.0 mm, respectively. For each PET scan, a dynamic series of 48 images was acquired (3 successive and identical sets of 16 images-each set lasting 40 mins-were acquired. Each set included 4 images of 15 secs, 2 of 30 secs, 3 of 1 mins, and 7 of 5 mins). Regions of interest were drawn on magnetic resonance images in the thalamus, caudate nucleus, cerebellum, and in the frontal, occipital and temporal cortices and reported on PET images after coregistration with the corresponding magnetic resonance images using a mutual information algorithm (http://brainvisa.free.fr). Concentrations of radioactivity in the regions of interests were calculated for each frame and expressed as pmol/mL, by dividing the radioactivity by the specific radioactivity at the time of the first injection. Figure 2 shows a typical time-concentration curve observed in frontal cortex (experiment 3). After the first i.v. administration of [
Results
Time-Concentration Curves
11 C]befloxatone, the brain radioactivity increased rapidly. In the cortex, thalamus, striatum, the radioactivity continuously increased until 30 mins. In contrast, the cerebellar time-concentration reached a decreased peak within the first minutes and then decreased slowly (details in Bottlaender et al, 2003) . After the first coinjection, the shape of the curves was different. In the cortex, thalamus, and striatum, the radioligand concentration peaked at 5 mins and then decreased. In the cerebellum, the peak was reached within the first minute and then decreased rapidly. The second coinjection resulted in a saturation of the MAO-A binding sites. After an early peak of radioactivity, a rapid washout was observed in all brain structures.
Model Parameter Estimates
Because of the very different shapes of the concentration curves after each of the three injections, all the parameters were estimated with good accuracy Tables 1 and 2 . In all brain structures, the quality of the fit obtained was good (Figure 2) . The standard errors of the parameter estimations were low (Table 2) for all the parameters except for k 5 and k 6 where the estimation was more hazardous. But, the quality of the fit without the nonspecific binding compartment was worse according to Akaike criterion. Therefore, the complete (four-compartment) model was used.
The interindividual variability of B 0 max was low in most of the structures (approximately 15%, Table 1 ). The variability was higher in the pons (25%), a fact explained by the inhomogeneity of this small structure.
The K d V R was found similar in all studied structures and was approximately 6 nmol/L, a value consistent with in vitro affinity of befloxatone: 1.3 nmol/L at 41C (Curet et al, 1996) .
Detailed Simulation of the Befloxatone Kinetics
With the multi-injection modeling approach, it is possible to simulate the time-concentration curves in all compartments. Figure 3 shows the simulation of the free, the specifically bound, and the nonspecifically bound labeled ligand concentrations (calculated using the input function and the model parameters in the frontal cortex of the experiment 3, Table 2 ).
After a tracer dose of [ 11 C]befloxatone, more than 96% of the radioactivity corresponded to labeled ligand bound to the MAO-A ( Figure 3A) . After 10 mins, the free ligand concentration was only 3% of the bound ligand, and the nonspecifically bound ligand concentration represented less than 1% of the bound ligand.
A similar pattern was observed after the first coinjection ( Figure 3A) . But, because of the large amount of unlabeled befloxatone, the distribution phase was slower. The free and nonspecifically bound fractions of labeled ligand reached a level of 5% and 1% of the bound ligand, respectively, 25 mins later.
The pattern observed after the second coinjection was different ( Figure 3B ). Because the MAO-A sites were saturated, the main part of the radioactivity peak corresponded to the distribution phase of the free ligand. After 20 mins, when the distribution phase was completed, the free and the bound ligand concentrations presented similar values whereas the nonspecifically bound ligand represented 60% of the bound ligand.
The unlabeled befloxatone injected at 40 mins (first coinjection) led to a partial binding site 
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occupancy (approximately 75% to 65% from 60 to 80 mins), whereas the high dose of unlabeled befloxatone injected at 80 mins (second coinjection) saturated almost all binding sites (more than 95% until the end of the experiment).
Influence of the Cerebral Blood Flow and of the Binding Site Concentration on [ 11 C]Befloxatone Kinetics
A typical PET study was used to simulate PET [ 11 C]befloxatone time-concentration curves after changes in cerebral blood flow (CBF) values or MAO binding site concentrations.
After tracer injection (high SA, Figure 4A ), a variation ( ± 20%) of parameter K 1 (assumed to represent CBF) led to ± 20% changes in [
11 C]befloxatone concentration and in specific binding. This was observed in all regions, as soon as 2 mins after the injection and remained constant until 40 mins. After a low SA injection (Figure 4B ), the same changes in K 1 values induced a change of less than 8% of [ 11 C]befloxatone concentration.
In contrast, variations ( ± 20%) of B 0 max led to smaller variations in [
11 C]befloxatone concentration (High SA, Figure 4A ): + 7% and À9%, respectively. However, after low SA injection, PET concentration changes were identical to B 0 max changes: + 18 and À19%, respectively ( Figure 4B ).
These results indicate that at high SA, PET curve is more sensitive to the CBF than to receptor density changes. Conversely, after a low SA injection where 65% to 75% of binding sites are occupied, the PET curve shape reflects the B 0 max changes.
Study of the Equilibrium States
After a tracer injection, the equilibrium states between the three main compartments of the model were simulated (Figure 5 ). The equilibrium state between the plasma and the free ligand compartments (the capillary exchange equilibrium state) was estimated by the ratio of the two concentrations plasma and free ligand. As the transfer rates between the plasma and the free ligand compartments are Figure 3 Simulations of the befloxatone kinetics in frontal cortex, after tracer injection and first co-injection (A), and after second co-injection (B). The befloxatone concentration is shown in all model compartments simulated using the model parameters given in Table 2 linear, the equilibrium is reached when the ratio of the two concentrations is a constant, equal to k 1 /k 2 . The equilibrium state between the free and the bound ligand compartments is also linear, and is reached when the ratio of the two concentrations is constant, equal to k on Â B 0 max /K off . Both ratios reached constant values after 30 mins as the consequence of a true equilibrium. Therefore, the PET protocol could be shortened to 90 mins.
Discussion
The aim of this study was to estimate the brain regional concentrations of MAO-A sites and all the ligand-binding site model parameters. This was performed during a single PET experiment by using the multi-injection modeling approach. (Morris et al, 2009; Gallezot et al, 2008) . In this study, the protocol included a tracer injection and two successive coinjections.
Experimental Protocol
The value of k 1 was high, reflecting indicating a high extraction fraction of the tracer. Similarly, the high value of k 2 allowed rapid washout of the unbound tracer. This rapidity makes a three-injection protocol possible despite of the short period of carbon-11.
The k off is six times greater than k on , explaining why [
11 C]befloxatone can be displaced relatively rapidly from its binding sites . However, this displacement needs 60 mins to be complete , thus, a coinjection with a partial saturating dose of befloxatone was chosen instead of a displacement with unlabeled befloxatone, for the second injection.
The third injection aimed at saturating all the MAO-A binding sites. This was achieve by a high amount of unlabeled befloxatone coinjected with [ 11 C]befloxatone to maintain a good count rate in the brain until the end of the PET experiment (120 mins).
Befloxatone appeared safe at pharmacologic doses in humans (Rosenzweig et al, 1998) . A single dose (p.o.) of 160 mg (573 mmol) was well tolerated in volunteers, as well as repeated doses of 80 mg per day (p.o.) for 7 days. After a single oral dose of 10 mg, mean peak plasma concentration (C max ) was 30 ± 10 ng/mL at 2 h (t max ). This high plasma concentration led to an abrupt inhibition of brain MAO-A, which was, again, well tolerated. Therefore, a multiinjection protocol-using a total amount of 20 mmol i.v. befloxatone-is currently underway to quantify the MAO-A density in patients with substance abuse disorders. Administered doses of radioactivity have been adapted to humans as effective doses of [ 11 C]befloxatone were estimated to be 7.1 mSv/MBq (personal data). The PET protocol has also been shortened to avoid a second radiosynthesis. Because the equilibrium states are observed at 30 mins after injection, now the PET scan lasts 90 mins (instead of 120 mins in baboons).
Specific Binding Parameters
At tracer dose, the specific binding parameter, k 3 (given by the product K on /V R Â B 0 max ), is 30 times higher than k off ( Table 2 ). The parameter k 3 is three times higher than k 1 (Table 2 ). This indicates that the capillary exchanges are the limiting factor for the binding to MAO-sites, explaining that, at tracer dose, the PET concentration as well as the specific binding is CBF dependent (Figure 4A ).
With a partial saturation, the parameter k 3 is no more linear and is given by K on /V R Â (B 0 max ÀBound). This situation was observed after the first coinjection where 65% to 75% of the binding sites are occupied by unlabeled befloxatone. Then, k 3 is reduced to 0.35±0.09 min À1 , a value close to that of k 1 . Therefore, the [ 11 C]befloxatone binding has low sensitivity to the CBF changes ( Figure 4B ).
The B 0 max values are similar in all the brain structures, with a maximum in cortical structures, striata, thalamus, and the lowest value is observed in the cerebellum. Using [
11 C]-harmine, Ginovart et al (2006) also found a similar regional pattern of the distribution volumes: DV B were 17 to 19 mL/mL in cortical structures and striata and 10.5 mL/mL in the cerebellum. In humans, Fowler (1987) , using [ 11 C]clorgyline, found very close values of the influx constant (K i from Patlak plot) in cortex, striatum thalamus, and brainstem. In studies in human brain in vitro, MAO-A site concentration was 1 to 3 pmol/ mg of protein (Cesura et al, 1990 ; O'Carroll et al, Figure 5 Study of the equilibrium states in the frontal cortex after tracer injection of [ 11 C]befloxatone (experiment 5). The dotted line (squares) represents the befloxatone concentration ratio in free over plasma compartment, the solid line (triangles) the befloxatone concentration ratio in bound over free compartment. Both curves reach a plateau at 30 mins indicating that the plasma, the free, and the bound ligand compartments are in equilibrium at this time.
1989; Saura et al, 1996) . Assuming a content of 100 mg proteins per mL tissue, the concentration of MAO-A can be estimated 100 to 300 pmol/mL tissue. These values are in the same range to those found in this study (Table 1) .
Positron emission tomography estimations of KdVR ranged from 5.7 to 6.9 nmol depending of the region of interest (Table 1) . This value is similar to that found in vitro by Curet et al (1996) using [ 3 H]befloxatone (K d = 1.3 nmol at 41C). This result suggests that, after saturating doses of unlabeled befloxatone used in the present PET protocol, there is no evidence of competition between endogenous substrates of MAO-A (dopamine, norepinephrine, 5HT) and befloxatone (Delforge et al, 2001b) . After full inhibition of MAO-A by befloxatone in rats (befloxatone 0.75 mg/kg, p.o.), there was a clear increase in extracellular concentration of dopamine and norepinephrine measured by microdialysis (Curet et al, 1996) . But, the in vitro study of the competition between [
3 H]befloxatone and these substrates showed that they have very low affinity for MAO-A (dopamine = 0.1 mmol, norepinephrine = 1 mmol; Curet et al, 1996) .
Nonspecific Binding
In PET studies, the nonspecific binding is often lumped together with the free ligand compartment. Neglecting the nonspecific compartment simplifies the model but is only justified if this nonspecific binding is negligible. This hypothesis was tested in our study. The quality of the fits was improved by introducing a nonspecific compartment. However, in all regions, the concentration of the nonspecific binding is very low after a tracer injection. For example, in cortical structures, k 5 is equal to 0.011±0.008 min À1 , whereas k 3 is 1.2±0.3 min À1 . At the equilibrium state, the nonspecifically bound ligand represents less than 1% of the PET concentration. Moreover, the equilibrium state between the free and the nonspecific ligand compartment is reach quickly (approximately 5 mins after a tracer injection) compared with the equilibrium states between the other compartments.
Therefore, the influence of the nonspecific binding on the PET data is minimal and, in further studies, the nonspecific compartment can be lumped together with the free compartment as the exchange is rapid even if the free and nonspecific biding are not negligible.
Conclusion
The multi-injection approach was used for the in vivo study of befloxatone kinetics. We have quantified for the first time in vivo, the density of the MAO-A binding sites in the brain. This protocol, allows the determination of all the other model parameters such as the K d , and the kinetic rate constants. The results show that [
11 C]befloxatone has interesting qualities for PET studies. The brain uptake is rapid and presents a high percentage of specific binding. [ 11 C]befloxatone appears to be an excellent PET ligand for pharmacologic and physiopathologic studies of the MAO-A in patients with substance abuse disorders. The present protocol has been adapted for human studies.
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